Patents by Inventor Christa Mayer

Christa Mayer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230242897
    Abstract: Provided herein are methods for purifying recombinant A Disintegrin-like and Metallopeptidase with Thrombospondin Type 1 Motif 13 (ADAMTS13) protein from a sample. The method comprises enriching for ADAMTS13 protein by chromatographically contacting the sample with hydroxyapatite under conditions that allow ADAMTS13 protein to appear in the eluate or supernatant from the hydroxylapatite. The methods may further comprise tandem chromatography with a mixed mode cation exchange/hydrophobic interaction resin that binds ADAMTS13 protein. Additional optional steps involve ultrafiltration/diafiltration, anion exchange chromatography, cation exchange chromatography, and viral inactivation. Also provided herein are methods for inactivating virus contaminants in protein samples, where the protein is immobilized on a support. Also provided herein are compositions of ADAMTS13 prepared according to said methods.
    Type: Application
    Filed: April 11, 2023
    Publication date: August 3, 2023
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Meinhard Hasslacher, Christian Fiedler, Christa Mayer, Artur Mitterer
  • Patent number: 11661593
    Abstract: Provided herein are methods for purifying recombinant A Disintegrin-like and Metallopeptidase with Thrombospondin Type 1 Motif 13 (ADAMTS13) protein from a sample. The method comprises enriching for ADAMTS13 protein by chromatographically contacting the sample with hydroxyapatite under conditions that allow ADAMTS13 protein to appear in the eluate or supernatant from the hydroxylapatite. The methods may further comprise tandem chromatography with a mixed mode cation exchange/hydrophobic interaction resin that binds ADAMTS13 protein. Additional optional steps involve ultrafiltration/diafiltration, anion exchange chromatography, cation exchange chromatography, and viral inactivation. Also provided herein are methods for inactivating virus contaminants in protein samples, where the protein is immobilized on a support. Also provided herein are compositions of ADAMTS13 prepared according to said methods.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: May 30, 2023
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Meinhard Hasslacher, Christian Fiedler, Christa Mayer, Artur Mitterer
  • Publication number: 20220275058
    Abstract: The present invention relates to a method for purifying a Factor VIII (FVIII) subspecies from a composition comprising FVIII, said method comprising an anion exchange chromatography step, a size exclusion chromatography step, and a concentration step. The invention also relates to a composition comprising a purified FVIII subspecies.
    Type: Application
    Filed: March 7, 2022
    Publication date: September 1, 2022
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Meinhard Hasslacher, Martin Feichtinger, Philipp M. Bärnthaler, Christa Mayer, Birgit Reipert, Mantas Malisauskas, Julia Anzengruber
  • Patent number: 11299533
    Abstract: The present invention relates to a method for purifying a Factor VIII (FVIII) subspecies from a composition comprising FVIII, said method comprising an anion exchange chromatography step, a size exclusion chromatography step, and a concentration step. The invention also relates to a composition comprising a purified FVIII subspecies.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: April 12, 2022
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Meinhard Hasslacher, Martin Feichtinger, Philipp M. Bärnthaler, Christa Mayer, Birgit Reipert, Mantas Malisauskas, Julia Anzengruber
  • Publication number: 20220041693
    Abstract: The present invention relates to a method for separating a mature von Willebrand Factor (mat-VWF) from von Willebrand Factor pro-peptide (VWF-PP) by incubating a composition comprising inducing dissociation of mat-VWF and VWF-PP by disruption of the non-covalently associated mat-VWF and VWF-PP, wherein said dissociation is induced by: (i) addition of at least one chelating agent, or (ii) increasing the pH to a pH of at least 7, and then collecting said mat-VWF to obtain a high purity, propeptide depleted mature VWF (mat-VWF).
    Type: Application
    Filed: February 8, 2021
    Publication date: February 10, 2022
    Inventors: Christian Fiedler, Meinhard Hasslacher, Christa Mayer
  • Patent number: 10934340
    Abstract: The present invention relates to a method for separating a mature von Willebrand Factor (mat-VWF) from von Willebrand Factor pro-peptide (VWF-PP) by incubating a composition comprising inducing dissociation of mat-VWF and VWF-PP by disruption of the non-covalently associated mat-VWF and VWF-PP, wherein said dissociation is induced by: (i) addition of at least one chelating agent, or (ii) increasing the pH to a pH of at least 7, and then collecting said mat-VWF to obtain a high purity, propeptide depleted mature VWF (mat-VWF).
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: March 2, 2021
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Christian Fiedler, Meinhard Hasslacher, Christa Mayer
  • Publication number: 20190382467
    Abstract: The present invention relates to a method for separating a mature von Willebrand Factor (mat-VWF) from von Willebrand Factor pro-peptide (VWF-PP) by incubating a composition comprising inducing dissociation of mat-VWF and VWF-PP by disruption of the non-covalently associated mat-VWF and VWF-PP, wherein said dissociation is induced by: (i) addition of at least one chelating agent, or (ii) increasing the pH to a pH of at least 7, and then collecting said mat-VWF to obtain a high purity, propeptide depleted mature VWF (mat-VWF).
    Type: Application
    Filed: March 20, 2019
    Publication date: December 19, 2019
    Inventors: Christian Fiedler, Meinhard Hasslacher, Christa Mayer
  • Publication number: 20190062403
    Abstract: The present invention relates to a method for purifying a Factor VIII (FVIII) subspecies from a composition comprising FVIII, said method comprising an anion exchange chromatography step, a size exclusion chromatography step, and a concentration step. The invention also relates to a composition comprising a purified FVIII subspecies.
    Type: Application
    Filed: June 22, 2018
    Publication date: February 28, 2019
    Applicants: Baxalta Incorporated, Baxalta GmbH
    Inventors: Meinhard HASSLACHER, Martin FEICHTINGER, Philipp M. BÄRNTHALER, Christa MAYER, Birgit REIPERT, Mantas MALISAUSKAS, Julia ANZENGRUBER
  • Patent number: 9315560
    Abstract: The present invention provides methods for purifying Von Willebrand factor (VWF) for increased removal of non-lipid enveloped viruses.
    Type: Grant
    Filed: August 20, 2010
    Date of Patent: April 19, 2016
    Assignees: BAXALTA INCORPORATED, BAXALTA GMBH
    Inventors: Artur Mitterer, Meinhard Hasslacher, Christa Mayer
  • Publication number: 20150104849
    Abstract: Provided herein are methods for purifying recombinant A Disintegrin-like and Metallopeptidase with Thrombospondin Type 1 Motif 13 (ADAMTS13) protein from a sample. The method comprises enriching for ADAMTS13 protein by chromatographically contacting the sample with hydroxyapatite under conditions that allow ADAMTS13 protein to appear in the eluate or supernatant from the hydroxylapatite. The methods may further comprise tandem chromatography with a mixed mode cation exchange/hydrophobic interaction resin that binds ADAMTS13 protein. Additional optional steps involve ultrafiltration/diafiltration, anion exchange chromatography, cation exchange chromatography, and viral inactivation. Also provided herein are methods for inactivating virus contaminants in protein samples, where the protein is immobilized on a support. Also provided herein are compositions of ADAMTS13 prepared according to said methods.
    Type: Application
    Filed: December 16, 2014
    Publication date: April 16, 2015
    Inventors: Meinhard Hasslacher, Christian Fiedler, Christa Mayer, Artur Mitterer
  • Patent number: 8945895
    Abstract: Provided herein are methods for purifying recombinant A Disintegrin-like and Metallopeptidase with Thrombospondin Type 1 Motif 13 (ADAMTS13) protein from a sample. The method comprises enriching for ADAMTS13 protein by chromatographically contacting the sample with hydroxyapatite under conditions that allow ADAMTS13 protein to appear in the eluate or supernatant from the hydroxylapatite. The methods may further comprise tandem chromatography with a mixed mode cation exchange/hydrophobic interaction resin that binds ADAMTS13 protein. Additional optional steps involve ultrafiltration/diafiltration, anion exchange chromatography, cation exchange chromatography, and viral inactivation. Also provided herein are methods for inactivating virus contaminants in protein samples, where the protein is immobilized on a support. Also provided herein are compositions of ADAMTS13 prepared according to said methods.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: February 3, 2015
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Meinhard Hasslacher, Christian Fiedler, Christa Mayer, Artur Mitterer
  • Patent number: 8388847
    Abstract: The invention relates generally to methods of concentrating mixtures including shear sensitive biopolymers, such as von Willebrand Factor. Conventional methods of concentrating biopolymers impart too much shear stress, which causes the degradation of shear sensitive biopolymers. The methods disclosed herein reduce the shear stress while maintaining a high rate of filtrate flux. Disclosed herein is a method for concentrating shear sensitive biopolymers including flowing a mixture with a shear sensitive biopolymer into a hollow fiber dialysis module to form a retentate having a shear sensitive biopolymer concentration that is greater than that of the mixture. Hollow fiber dialysis modules have high filtrate fluxes and low shear rates at low flow rates. This ensures a high product yield and minimal loss of shear sensitive biopolymers.
    Type: Grant
    Filed: August 27, 2009
    Date of Patent: March 5, 2013
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Artur Mitterer, Meinhard Hasslacher, Christa Mayer
  • Publication number: 20120076779
    Abstract: The present invention provides, among other aspects, storage stabile aqueous formulations of labile proteins at a mildly acidic to neutral pH. The present invention also provides methods for stabilizing a labile therapeutic protein composition at a mildly acidic to neutral pH. Advantageously, the methods and formulations provided herein allow stabile aqueous compositions of labile proteins at mildly acidic to neutral pH useful for parenteral administration.
    Type: Application
    Filed: September 16, 2011
    Publication date: March 29, 2012
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventors: Harald Arno Butterweck, Theresa Friederike Bauer, Lucia Hofbauer, Wolfgang Teschner, Oliver Zoechling, Hans-Peter Schwarz, Christa Mayer, Meinhard Hasslacher
  • Patent number: 8058411
    Abstract: The present invention relates to a method for producing a mature von Willebrand Factor (VWF) from von Willebrand Factor pro-peptide comprising the steps: immobilizing VWF pro-peptide on an ion exchange resin, incubating the immobilized VWF pro-peptide with furin to obtain immobilized mature VWF, and isolating mature VWF from the ion exchange resin by elution.
    Type: Grant
    Filed: May 16, 2008
    Date of Patent: November 15, 2011
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Wolfgang Mundt, Artur Mitterer, Meinhard Hasslacher, Christa Mayer
  • Publication number: 20110092681
    Abstract: The present invention provides methods for purifying Von Willebrand factor (VWF) for increased removal of non-lipid enveloped viruses.
    Type: Application
    Filed: August 20, 2010
    Publication date: April 21, 2011
    Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.
    Inventors: ARTUR MITTERER, MEINHARD HASSLACHER, CHRISTA MAYER
  • Publication number: 20110081700
    Abstract: Provided herein are methods for purifying recombinant A Disintegrin-like and Metallopeptidase with Thrombospondin Type 1 Motif 13 (ADAMTS13) protein from a sample. The method comprises enriching for ADAMTS13 protein by chromatographically contacting the sample with hydroxyapatite under conditions that allow ADAMTS13 protein to appear in the eluate or supernatant from the hydroxylapatite. The methods may further comprise tandem chromatography with a mixed mode cation exchange/hydrophobic interaction resin that binds ADAMTS13 protein. Additional optional steps involve ultrafiltration/diafiltration, anion exchange chromatography, cation exchange chromatography, and viral inactivation. Also provided herein are methods for inactivating virus contaminants in protein samples, where the protein is immobilized on a support. Also provided herein are compositions of ADAMTS13 prepared according to said methods.
    Type: Application
    Filed: July 30, 2010
    Publication date: April 7, 2011
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventors: Meinhard Hasslacher, Christian Fiedler, Christa Mayer, Artur Mitterer
  • Publication number: 20100051550
    Abstract: The invention relates generally to methods of concentrating mixtures including shear sensitive biopolymers, such as von Willebrand Factor. Conventional methods of concentrating biopolymers impart too much shear stress, which causes the degradation of shear sensitive biopolymers. The methods disclosed herein reduce the shear stress while maintaining a high rate of filtrate flux. Disclosed herein is a method for concentrating shear sensitive biopolymers including flowing a mixture with a shear sensitive biopolymer into a hollow fiber dialysis module to form a retentate having a shear sensitive biopolymer concentration that is greater than that of the mixture. Hollow fiber dialysis modules have high filtrate fluxes and low shear rates at low flow rates. This ensures a high product yield and minimal loss of shear sensitive biopolymers.
    Type: Application
    Filed: August 27, 2009
    Publication date: March 4, 2010
    Applicants: BAXTER HEALTHCARE S.A, BAXTER INTERNATIONAL INC.
    Inventors: Artur Mitterer, Meinhard Hasslacher, Christa Mayer
  • Publication number: 20090029918
    Abstract: The present invention relates to a method for producing a mature von Willebrand Factor (VWF) from von Willebrand Factor pro-peptide comprising the steps: immobilizing VWF pro-peptide on an ion exchange resin, incubating the immobilized VWF pro-peptide with furin to obtain immobilized mature VWF, and isolating mature VWF from the ion exchange resin by elution.
    Type: Application
    Filed: May 16, 2008
    Publication date: January 29, 2009
    Applicants: Baxter International Inc., Baxter Healthcare SA
    Inventors: Wolfgang Mundt, Artur Mitterer, Meinhard Hasslacher, Christa Mayer